Cardiology Online - International Academy of Cardiology
 
»search site
The International Academy of Cardiology is dedicated to the advancement of global research in cardiovascular medicine through the support of scientific meetings and publications.
   Home Page
   Congresses
   Journals
   Organizations
   Institutions
   Books
   Research
   Guidelines
   Discussion Groups
   Webcourses
   Websites
   Job Opportunities
   Contact Us




 

 

 

 


IAC 2018

 

NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS): CARDIOVASCULAR EVENTS ARE RELATED PRIMARILY TO IMPACT OF NSAIDS ON BLOOD PRESSURE RATHER THAN TO COX SELECTIVITY (Invited Lecture)



Jeffrey S. Borer, M.D. , Cell Biology, Radiology, Public Health and Surgery, SUNY Downstate, New York, NY, USA

 

Nonsteroidal anti-inflammatory drugs (NSAIDs), both non-selective and selective cyclooxygenase-2 (COX-2) inhibitors, are very widely prescribed, but they may cause increased blood pressure (BP) and adverse cardiovascular (CV) events. PRECISION-ABPM, a 4 month double-blind, non-inferiority substudy of PRECISION, was conducted in 444 pts (mean age 6210 yrs) with osteo- or rheumatoid arthritis with relatively high CAD risk at 60 sites to determine BP effects (by 24 hr ABP) of the selective COX-2 inhibitor celecoxib (100-200mg bid) vs. the non-selective NSAIDs naproxen (375-500mg bid) and ibuprofen (600-800mg tid). The change in mean 24-hour SBP with celecoxib, ibuprofen and naproxen was -0.3mmHg (95% CI, -2.25, 1.74), 3.7 (95% CI, 1.72, 5.58) and 1.6mmHg (95% CI, -0.40, 3.57), respectively. BP difference was -3.9mmHg (p=0.009) between celecoxib and ibuprofen, -1.8mmHg (p=0.12) between celecoxib and naproxen, and -2.1mmHg (p=0.08) between naproxen and ibuprofen. The percentage of patients with normal baseline BP who developed hypertension was 23.2% for ibuprofen, 19.0% for naproxen and 10.3% for celecoxib (odds ratio 0.39, p=0.004 and odds ratio 0.49, p=0.03 vs. ibuprofen and naproxen, respectively). In PRECISION-ABPM, allocation to the non-selective NSAID ibuprofen, compared with the COX-2 selective inhibitor celecoxib associated with a significant increase of systolic BP, and a higher incidence of new-onset hypertension.

 

 

©1998-2020 Cardiology Online, Inc. All rights reserved.
Cardiology Online is a registered trademark of Cardiology Online, Inc.
CardiologyOnline.com